Overview

Rich Pharmaceuticals is a biopharmaceutical company that is focused on the development of its lead product, RP-323 (12-O-tetradecanoylphorbol-13-acetate), for the treatment of acute myelogenous leukemia (AML) in refractory patients. The basis for the interest of the Company to pursue clinical development of TPA in these and possibly other indications is the result of  Prof. Richard Chang.  He has conducted research on TPA for many years and have become an expert in the characteristics of this molecule. Their findings form the scientific basis for the clinical use of TPA.

AML Studies with TPA

Encouraged by the clinical results with TPA in China, Roger Strair MD, PhD, a leading oncologist at the University of Medicine and Dentistry at Rutgers University, obtained an investigator IND and successfully completed a Phase 1 study in patients, the majority of whom had relapsed/refractory AML. Rich Pharmaceuticals was encouraged by Dr. Strair to conduct a Phase 2 study in relapsed/refractory AML. A Phase 2 study is currently underway under the direction of Dr. Strair who is actively enrolling appropriate patients in this study.  Since this study, UMDNJ has changed their name to Rutgers, Cancer Institute of New Jersey where Rich Pharmaceuticals plans on conduction P2 clinical trials.

Legal Grounds

Rich Pharmaceuticals is protected by an issued “use patent” that gives sole rights to the Company to use the intravenous administration of TPA for therapeutic purposes. Since TPA can only be administered for therapeutic purposes by this route, this patent provides complete protection for the use of TPA for any other use.

News

May 9th, 2017

Rich Pharmaceuticals’s Division CannCodex, Releases List of Conditional Use Permits Issued in California to Medicinal Cannabis Businesses
View Release

April 10th, 2017

Rich Pharmaceuticals Welcomes New Board Member
View Release

April 6th, 2017

Rich Pharmaceuticals announces Industry Veteran to Join CannCodex
View Release

» View All News

Stock Price